Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 100

Sort by

Sort Order Select

Journal Articles

Potential and Realized Cost Savings with the Use of the Biosimilar Grastofil Vs Neupogen

Hishaam Bhimji, BSP, Dean Eurich, PhD, Kerry Mansell, PharmD, MBA, Holly Mansell, PharmD

Blood (2019) 134 (Supplement_1): 2126.

https://doi.org/10.1182/blood-2019-122751

Published: 2019

Journal Articles

Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study

Vladimir Hanes, MD, Jean Pan, Daniel T. Mytych, PhD, David Chien, MD, Vincent Chow

Blood (2019) 134 (Supplement_1): 3520.

https://doi.org/10.1182/blood-2019-128621

Published: 2019

Journal Articles

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

Blood (2019) 134 (Supplement_1): 2878.

https://doi.org/10.1182/blood-2019-130603

Published: 2019

Journal Articles

Rapid Infusion with CT-P10 in Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia: Interim Six Month Follow-up from a European Non-Interventional Post-Authorisation Safety Study

Mark Bishton, Pier Luigi Zinzani, MD PhD, Scott Marshall, Veronica Conteh, Alicia Rodríguez Fernández, SooKyoung Kim, Young Nam Lee

Blood (2019) 134 (Supplement_1): 4135.

https://doi.org/10.1182/blood-2019-121957

Published: 2019

Journal Articles

Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data

Aleksandr Kulagin, Vadim Ptushkin, MD PhD Professor, Elena Lukina, MD PhD Professor, Elena Gapchenko, MD, Oksana Markova, MD MSc, Eugene Zuev, MD, Dmitry Kudlay, MD PhD Professor

Blood (2019) 134 (Supplement_1): 3748.

https://doi.org/10.1182/blood-2019-125693

Published: 2019

Journal Articles

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Christian Buske, MD PhD, Larry W Kwak, MD PhD, Wojciech Jurczak, MD PhD, Juan-Manuel Sancho, MD PhD, Edvard Zhavrid, MD PhD, Jin Seok Kim, MD PhD, Jose Angel Hernandez-Rivas, MD PhD, Aliaksandr Prokharau, MD PhD, Mariana Vasilica, MD PhD, Rajnish Nagarkar, MD PhD, Gayane Tumyan, DMSc, MD PhD, Won-Seog Kim, MD PhD, Michinori Ogura, MD PhD, Sang Joon Lee, PhD, Sung Hyun Kim, PhD, Keum Young Ahn, PhD

Blood (2019) 134 (Supplement_1): 1528.

https://doi.org/10.1182/blood-2019-126379

Published: 2019

Journal Articles

Clinical Characteristics of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): A Retrospective Chart Review Study

Vladimir Hanes, MD, Jean Pan, Vincent Chow

Blood (2019) 134 (Supplement_1): 4789.

https://doi.org/10.1182/blood-2019-130409

Published: 2019

Journal Articles

Single Centre UK Comparison of Biosimilar Rituximab (Truxima) with the Originator (MabThera) in Patients with Immune Mediated Thrombotic Thrombocytopenic Purpura

Matthew J. Stubbs, MBBS, MRCP, FRCPath, Ryan Low, MBChB, Siobhan McGuckin, Rosalind Newton, John-Paul Westwood, MD, Mari Thomas, PhD, Simon Cheesman, BPharm, Marie Scully, MD MRCP, FRCPath

Blood (2018) 132 (Supplement 1): 3750.

https://doi.org/10.1182/blood-2018-99-114765

Published: 2018

Journal Articles

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera ® ) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

Jeff Sharman, MD, Anna Marina Liberati, MD, Rodrigo Santucci Silva, MD, Igor Aurer, MD PhD, Jeffery Robbins, MS, Julie Ann Rosenberg, MD, Tahira Khan, MD MS, Ann Alcasid

Blood (2018) 132 (Supplement 1): 394.

https://doi.org/10.1182/blood-2018-99-111248

Published: 2018

Journal Articles

Biosimilar G-CSF Versus Originator G-CSF for Autologous Peripheral Blood Stem Cell Mobilization: A Comparative Analysis of Mobilization and Engraftment

Julie Stakiw, MD FRCPC, Waleed Sabry, MSc, MD PhD, Mohamed Elemary, MD, Mark J. Bosch, MD, Pat Danyluk, Bsc. Pharm, Vibhuti Aggarwal, Bsc, Prosanta Mondal, PhD

Blood (2018) 132 (Supplement 1): 3345.

https://doi.org/10.1182/blood-2018-99-115341

Published: 2018

Journal Articles

Does Use of Biosimilar G-CSF Change Plerixafor Utilization during Stem Cell Mobilization for Autologous Stem Cell Transplant?

Nadine Abdallah, MD, Seongho Kim, PhD, Asif Alavi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2018) 132 (Supplement 1): 4557.

https://doi.org/10.1182/blood-2018-99-118400

Published: 2018

Journal Articles

Comparison of Pegfilgrastim and Filgrastim to Prevent Neutropenic Fever during Consolidation with High Dose Cytarabine for Acute Myeloid Leukemia

Evan Field, Paolo F Caimi, MD, Brenda Cooper, MD, Jane Little, MD, Ehsan Malek, MD, Leland Metheny, MD, Marcos de Lima, MD, Pingfu Fu, Ben Tomlinson, MD

Blood (2018) 132 (Supplement 1): 1404.

https://doi.org/10.1182/blood-2018-99-118336

Published: 2018

Journal Articles

Cost-Effective Use of White Blood Cell Growth Factors in the Veterans Administration

Kevin Knopf, MD, William Hrureshky, Bryan Love, Leann Norris, Charles L. Bennett, MD PhD

Blood (2018) 132 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2018-99-119724

Published: 2018

Journal Articles

Subcutaneous Versus Intravenous Rituximab in Non-Hodgkin Lymphoma Treated with R-CHOP: Economic Modeling for the US

Ali McBride, PharmD, MS, Sanjeev Balu, PhD, Kim Campbell, PharmD, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2018) 132 (Supplement 1): 4776.

https://doi.org/10.1182/blood-2018-99-113283

Published: 2018

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2018) 132 (Supplement 1): 121.

https://doi.org/10.1182/blood-2018-99-112093

Published: 2018

Journal Articles

Assessing the Need for a Biosimilar: A Systematic Literature Review of the Treatment Burden of Rituximab in Hematological Malignancies

Elizabeth James, Holly Trautman, Gerard Hoehn, PhD, Erika Szabo, Boxiong Tang, MD PhD

Blood (2018) 132 (Supplement 1): 5908.

https://doi.org/10.1182/blood-2018-99-110953

Published: 2018

Journal Articles

Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

Ali McBride, PharmD,MS, Andriy Krendyukov, MD MBA, Nicola Mathieson, Kim Campbell, PharmD, Sanjeev Balu, PhD, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2018) 132 (Supplement 1): 2251.

https://doi.org/10.1182/blood-2018-99-116315

Published: 2018

Journal Articles

Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study

Ali McBride, PharmD,MS, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham, PhD RN, Sanjeev Balu

Blood (2017) 130 (Supplement 1): 3380.

https://doi.org/10.1182/blood.V130.Suppl_1.3380.3380

Published: 2017

Journal Articles

A Systematic Literature Review of Overall Survival and Delivered Dose Intensity in Cancer Patients Receiving Chemotherapy and G-CSF in Randomized Control Trials

Gary H. Lyman, MD MPH, FRCP, Lillian Yau, Roumen Nakov, Andriy Krendyukov

Blood (2017) 130 (Supplement 1): 3424.

https://doi.org/10.1182/blood.V130.Suppl_1.3424.3424

Published: 2017

Journal Articles

Evaluation of the Safety and Tolerability of Rapid Infusion of Biosimilar Rituximab Truxima® — the University College London Hospitals (UCLH) Experience

Raakhee Shah, MPharm, Simon Cheesman, BPharm, Kirit M Ardeshna, MD, Kate Cwynarski, MD, David C. Linch, FRCP, Andres E. Virchis, FRCP, FRCPath, Jonathan Richard Lambert, Christopher Mcnamara, William Townsend

Blood (2017) 130 (Supplement 1): 3387.

https://doi.org/10.1182/blood.V130.Suppl_1.3387.3387

Published: 2017

NARROW

Potential and Realized Cost Savings with the Use of the Biosimilar Grastofil Vs Neupogen

Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

Rapid Infusion with CT-P10 in Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia: Interim Six Month Follow-up from a European Non-Interventional Post-Authorisation Safety Study

Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Clinical Characteristics of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): A Retrospective Chart Review Study

Single Centre UK Comparison of Biosimilar Rituximab (Truxima) with the Originator (MabThera) in Patients with Immune Mediated Thrombotic Thrombocytopenic Purpura

A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera ® ) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)

Biosimilar G-CSF Versus Originator G-CSF for Autologous Peripheral Blood Stem Cell Mobilization: A Comparative Analysis of Mobilization and Engraftment

Does Use of Biosimilar G-CSF Change Plerixafor Utilization during Stem Cell Mobilization for Autologous Stem Cell Transplant?

Comparison of Pegfilgrastim and Filgrastim to Prevent Neutropenic Fever during Consolidation with High Dose Cytarabine for Acute Myeloid Leukemia

Cost-Effective Use of White Blood Cell Growth Factors in the Veterans Administration

Subcutaneous Versus Intravenous Rituximab in Non-Hodgkin Lymphoma Treated with R-CHOP: Economic Modeling for the US

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

Assessing the Need for a Biosimilar: A Systematic Literature Review of the Treatment Burden of Rituximab in Hematological Malignancies

Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study

A Systematic Literature Review of Overall Survival and Delivered Dose Intensity in Cancer Patients Receiving Chemotherapy and G-CSF in Randomized Control Trials

Evaluation of the Safety and Tolerability of Rapid Infusion of Biosimilar Rituximab Truxima® — the University College London Hospitals (UCLH) Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only